Table 1
| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) | 1 | Y | 1 MK-3475 (pembrolizumab) | 56 | 31 | 15 | 9 | 4 | 3 | 0 | 02/06/2017 | 105 | 44 |
| 31 | 15 | 9 | 4 | 3 | 0 | |||||||||
| S1607-MELAN, Adv, T-VEC, MK-3475 | 1 | Y | 1 T-VEC + MK-3475(pembrolizumab) | 64 | 23 | 19 | 9 | 3 | 1 | 0 | 06/05/2018 | 69 | 27 | |
| 23 | 19 | 9 | 3 | 1 | 0 | |||||||||
| S1616-MELAN, Adv, Ipilimumab ± Nivolumab | 1 | Y | 1 Ipilimumab | 94 | 17 | 9 | 7 | 4 | 1 | 1 | 10/23/2017 | 232 | 95 | |
| 2 Nivolumab + Ipilimumab | 50 | 34 | 22 | 15 | 3 | 2 | ||||||||
| 67 | 43 | 29 | 19 | 4 | 3 | |||||||||
| S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab | 1 | Y | 1 Adjuvant Arm | 556 | 29 | 29 | 25 | 12 | 6 | 0 | 02/15/2019 | 302 | 126 | |
| 2 Neoadjuvant Pembrolizumab | 27 | 27 | 26 | 11 | 3 | 0 | ||||||||
| 56 | 56 | 51 | 23 | 9 | 0 | |||||||||
| 2 | Y | 3 Surgery | 556 | 41 | 41 | 38 | 23 | 8 | 2 | 02/15/2019 | ||||
| 41 | 41 | 38 | 23 | 8 | 2 | |||||||||
| 3 | Y | 4 Post-Surgery Pembro | 556 | 29 | 29 | 28 | 24 | 8 | 0 | 02/15/2019 | ||||
| 29 | 29 | 28 | 24 | 8 | 0 | |||||||||
| Yes | EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T | 1 | E | Total Registrations | 42 | 12 | 7 | 2 | 1 | 0 | 11/03/2015 | 289 | 122 | |
| 42 | 12 | 7 | 2 | 1 | 0 | |||||||||
| 2 | E | Total Registrations | 14 | 2 | 1 | 0 | 0 | 0 | 11/03/2015 | |||||
| 14 | 2 | 1 | 0 | 0 | 0 | |||||||||
| EA6141-Melan, Avd, Nivolumab+Ipi ± Sargmostim | 1 | E | Total Registrations | 36 | 0 | 0 | 0 | 0 | 0 | 03/25/2016 | 209 | 82 | ||
| 36 | 0 | 0 | 0 | 0 | 0 | |||||||||
| No | EA6174-Merkel, Adjuvant Pembrolizumab vs Observation | 1 | E | Total Registrations | 2 | 2 | 2 | 1 | 1 | 0 | 05/01/2019 | 114 | 64 | |
| 2 | 2 | 2 | 1 | 1 | 0 | |||||||||